About
239.01USD+1.56 +0.66%
Closed • Updated at 13:38 GMT+00:00Market Cap$15.00B
Volume835.3K
Beta0.19
RSI75.47
Gross Margin72.85%
Jazz Pharmaceuticals Plc — investor relations, events, news, and company updates on 6ix.
Latest News
May 5 2026
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
Apr 30 2026
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
Apr 27 2026
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Apr 22 2026
HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties
Apr 21 2026
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
Translate